Literature DB >> 1517360

The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients.

N A Samaan1, P N Schultz, R C Hickey, H Goepfert, T P Haynie, D A Johnston, N G Ordonez.   

Abstract

This study analyzed the impact of prognostic variables of age, sex, histopathological diagnosis, extent of disease at diagnosis, and surgical intervention on well differentiated thyroid carcinoma and how surgical treatment, radioactive iodine, and radiotherapy influence the patients' outcomes. There have been 1599 patients with well differentiated thyroid cancer treated and followed at the University of Texas M.D. Anderson Cancer Center from 1948 to 1989. The median follow-up for all patients was 11.0 yr, with the maximum follow-up being 43 yr and the minimum follow-up being 1 yr. The patients were predominantly female (2.3:1), with papillary (81%) and intrathyroidal carcinomas (42%) at the time of diagnosis. Sixty-six percent of the patients had a total thyroidectomy, 7% received external radiotherapy, and 46% had radioactive iodine as part of the treatment of the original disease; the overall recurrence rate was 23%, and the death rate was 11%. This study showed that treatment with radioactive iodine was the single most powerful prognostic indicator for increased disease-free interval (P less than 0.001) and that its use significantly increased survival as well. No benefit was obtained from treatment with external radiotherapy. Children had the best overall survival, but of the adult patients, females who had intrathyroidal papillary disease treated with total thyroidectomy, who had been given radioactive iodine, and whose disease had been diagnosed between 20-59 yr of age had the best prognosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1517360     DOI: 10.1210/jcem.75.3.1517360

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  95 in total

Review 1.  Thyroid cancer surgery.

Authors:  R Udelsman
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

2.  Amplification of thymosin beta 10 and AKAP13 genes in metastatic and aggressive papillary thyroid carcinomas.

Authors:  Liliána Z Fehér; Gábor Pocsay; László Krenács; Agnes Zvara; Enikő Bagdi; Réka Pocsay; Géza Lukács; Ferenc Győry; Andrea Gazdag; Erzsébet Tarkó; László G Puskás
Journal:  Pathol Oncol Res       Date:  2011-12-11       Impact factor: 3.201

3.  Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer.

Authors:  A S Alzahrani; G Mohamed; A Al Shammary; S Aldasouqi; S Abdal Salam; M Shoukri
Journal:  J Endocrinol Invest       Date:  2005-06       Impact factor: 4.256

4.  Longer-term outcomes of radiofrequency ablation for locally recurrent papillary thyroid cancer.

Authors:  Sae Rom Chung; Jung Hwan Baek; Young Jun Choi; Jeong Hyun Lee
Journal:  Eur Radiol       Date:  2019-02-25       Impact factor: 5.315

5.  Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons.

Authors:  Hiroshi Takami; Yasuhiro Ito; Takahiro Okamoto; Akira Yoshida
Journal:  World J Surg       Date:  2011-01       Impact factor: 3.352

6.  Percutaneous Microwave Ablation of Metastatic Lymph Nodes from Papillary Thyroid Carcinoma: Preliminary Results.

Authors:  Wei Zhou; Yudong Chen; Lu Zhang; Xiaofeng Ni; Shangyan Xu; Weiwei Zhan
Journal:  World J Surg       Date:  2019-04       Impact factor: 3.352

7.  Disease severity and radioactive iodine use for thyroid cancer.

Authors:  M R Haymart; D G Muenz; A K Stewart; J J Griggs; M Banerjee
Journal:  J Clin Endocrinol Metab       Date:  2013-01-15       Impact factor: 5.958

8.  The change in surgical practice from subtotal to near-total or total thyroidectomy in the treatment of patients with benign multinodular goiter.

Authors:  Serdar Tezelman; Ismail Borucu; Yasemin Senyurek Giles; Fatih Tunca; Tarik Terzioglu
Journal:  World J Surg       Date:  2009-03       Impact factor: 3.352

9.  Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis?

Authors:  Elif Hindié; Didier Mellière; Françoise Lange; Iyad Hallaj; Claire de Labriolle-Vaylet; Christian Jeanguillaume; Jacques Lange; Léon Perlemuter; Serge Askienazy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-07       Impact factor: 9.236

10.  Should patients with remnants from thyroid microcarcinoma really not be treated with iodine-131 ablation?

Authors:  Rosj Gallicchio; Sabrina Giacomobono; Daniela Capacchione; Anna Nardelli; Francesco Barbato; Antonio Nappi; Teresa Pellegrino; Giovanni Storto
Journal:  Endocrine       Date:  2013-03-28       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.